Fujirebio Multiplex Ovarian Cancer Assay Development Will Take 1-2 Years
This article was originally published in The Gray Sheet
Executive Summary
Fujirebio Diagnostics plans to develop a multiplex assay for early detection of ovarian cancer that combines mesothelin and HE4 markers with the firm's CA 125 II serum-based assay